Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice

Journal of Virology

Volumn 84, Issue 19, 2010, Pages 9907-9919

  Meisinger Henschel, Christine ^a   Späth, Michaela ^a   Lukassen, Susanne ^a   Wolferstätter, Michael ^a   Kachelriess, Heike ^a   Baur, Karen ^a   Dirmeier, Ulrike ^a   Wagner, Markus ^a   Chaplin, Paul ^a   Suter, Mark ^a,b   Hausmann, Jürgen ^a  

^a Bavarian Nordic GmbH   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CHICKEN; EMBRYO; FEMALE; FIBROBLAST; GENE DELETION; HAMSTER; HELA CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; MAMMAL CELL; MODIFIED VACCINIA VIRUS ANKARA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; POXVIRUS INFECTION; PRIORITY JOURNAL; RABBIT; VACCINIA VIRUS; VIRUS GENE; VIRUS REPLICATION; VIRUS VIRULENCE; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CHICK EMBRYO; CYTOPATHOGENIC EFFECT; GENETIC RECOMBINATION; GENETICS; PATHOGENICITY; PHYSIOLOGY; VACCINIA; VIROLOGY; VIRULENCE; VIRUS CULTURE; VIRUS GENOME;

BACTERIA (MICROORGANISMS); MAMMALIA; MUS; ORYCTOLAGUS CUNICULUS; VACCINIA VIRUS; VACCINIA VIRUS ANKARA;

ANIMALS; CELL LINE; CHICK EMBRYO; CHROMOSOMES, ARTIFICIAL, BACTERIAL; CYTOPATHOGENIC EFFECT, VIRAL; FEMALE; GENE DELETION; GENOME, VIRAL; HUMANS; MICE; MICE, INBRED BALB C; PHENOTYPE; RABBITS; RECOMBINATION, GENETIC; VACCINIA; VACCINIA VIRUS; VIRULENCE; VIRUS CULTIVATION; VIRUS REPLICATION;

EID: 77956845506     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00756-10     Document Type: Article

References (62)

1. Alcami, A., and G. L. Smith. 1992. A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 71:153-167.
2. Antoine, G., F. Scheiflinger, F. Dorner, and F. G. Falkner. 1998. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244:365-396.
3. Astua-Monge, G., A. Lyznik, V. Jones, S. A. Mackenzie, and C. E. Vallejos. 2002. Evidence for a prokaryotic insertion-sequence contamination in eukaryotic sequences registered in different databases. Theor. Appl. Genet. 104:48-53.
4. Beard, P. M., G. C. Froggatt, and G. L. Smith. 2006. Vaccinia virus kelch protein A55 is a 64 kDa intracellular factor that affects virus-induced cytopathic effect and the outcome of infection in a murine intradermal model. J. Gen. Virol. 87:1521-1529.
5. Belyakov, I. M., P. Earl, A. Dzutsev, V. A. Kuznetsov, M. Lemon, L. S. Wyatt, J. T. Snyder, J. D. Ahlers, G. Franchini, B. Moss, and J. A. Berzofsky. 2003. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. U. S. A. 100:9458-9463.
6. Blanchard, T. J., A. Alcami, P. Andrea, and G. L. Smith. 1998. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J. Gen. Virol. 79:1159-1167.
7. Boukamp, P., R. T. Petrussevska, D. Breitkreutz, J. Hornung, A. Markham, and N. E. Fusenig. 1988. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J. Cell Biol. 106:761-771.
8. Buller, R. M., and G. J. Palumbo. 1992. Safety and attenuation of vaccinia virus, p. 235-268. In M. M. Binns and G. L. Smith (ed.), Recombinant poxviruses. CRC Press, Boca Raton, FL.
9. Carroll, M. W., and B. Moss. 1997. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238:198-211.
10. Chakrabarty, K., W. Wu, J. L. Booth, E. S. Duggan, N. N. Nagle, K. M. Coggeshall, and J. P. Metcalf. 2007. Human lung innate immune response to Bacillus anthracis spore infection. Infect. Immun. 75:3729-3738.
11. Condit, R. C., N. Moussatche, and P. Traktman. 2006. In a nutshell: structure and assembly of the vaccinia virion. Adv. Virus Res. 66:31-124.
12. Cordeiro, J. V., S. Guerra, Y. Arakawa, M. P. Dodding, M. Esteban, and M. Way. 2009. F11-mediated inhibition of RhoA signalling enhances the spread of vaccinia virus in vitro and in vivo in an intranasal mouse model of infection. PLoS One 4:e8506.
13. Dai, K., Y. Liu, M. Liu, J. Xu, W. Huang, X. Huang, L. Liu, Y. Wan, Y. Hao, and Y. Shao. 2008. Pathogenicity and immunogenicity of recombinant Tiantan vaccinia virus with deleted C12L and A53R genes. Vaccine 26:5062-5071.
14. Datsenko, K. A., and B. L. Wanner. 2000. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl. Acad. Sci. U. S. A. 97:6640-6645.
15. Domi, A., and B. Moss. 2002. Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 99:12415-12420.
16. Drexler, I., K. Heller, B. Wahren, V. Erfle, and G. Sutter. 1998. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 79:347-352.
17. Earl, P. L., J. L. Americo, L. S. Wyatt, L. A. Eller, D. C. Montefiori, R. Byrum, M. Piatak, J. D. Lifson, R. R. Amara, H. L. Robinson, J. W. Huggins, and B. Moss. 2007. Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate. Virology 366:84-97.
18. Earl, P. L., J. L. Americo, L. S. Wyatt, L. A. Eller, J. C. Whitbeck, G. H. Cohen, R. J. Eisenberg, C. J. Hartmann, D. L. Jackson, D. A. Kulesh, M. J. Martinez, D. M. Miller, E. M. Mucker, J. D. Shamblin, S. H. Zwiers, J. W. Huggins, P. B. Jahrling, and B. Moss. 2004. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428:182-185.
19. Ferrier-Rembert, A., R. Drillien, J. N. Tournier, D. Garin, and J. M. Crance. 2008. Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine. Vaccine 26:1794-1804.
20. Goebel, S. J., G. P. Johnson, M. E. Perkus, S. W. Davis, J. P. Winslow, and E. Paoletti. 1990. The complete DNA sequence of vaccinia virus. Virology 179:247-263.
21. Harte, M. T., I. R. Haga, G. Maloney, P. Gray, P. C. Reading, N. W. Bartlett, G. L. Smith, A. Bowie, and L. A. O'Neill. 2003. The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J. Exp. Med. 197:343-351.
22. Kaerber, G. 1931. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch. Exp. Pathol. Pharmakol. 162:480-483.
23. Kotwal, G. J., A. W. Hugin, and B. Moss. 1989. Mapping and insertional mutagenesis of a vaccinia virus gene encoding a 13,800-Da secreted protein. Virology 171:579-587.
24. Kovarik, A., M. A. Matzke, A. J. Matzke, and B. Koulakova. 2001. Transposition of IS10 from the host Escherichia coli genome to a plasmid may lead to cloning artefacts. Mol. Genet. Genomics 266:216-222.
25. Legrand, F. A., P. H. Verardi, L. A. Jones, K. S. Chan, Y. Peng, and T. D. Yilma. 2004. Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes. J. Virol. 78:2770-2779.
26. Mayr, A., V. Hochstein-Mintzel, and H. Stickl. 1975. Passage history, properties, and use of the attenuated vaccinia virus strain MVA. Infection 3:6-14.
27. Mayr, A., H. Stickl, H. K. Muller, K. Danner, and H. Singer. 1978. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism. Zentralbl. Bakteriol. B 167:375-390.
28. McFadden, G. 2005. Poxvirus tropism. Nat. Rev. Microbiol. 3:201-213.
29. Meisinger-Henschel, C., M. Schmidt, S. Lukassen, B. Linke, L. Krause, S. Konietzny, A. Goesmann, P. Howley, P. Chaplin, M. Suter, and J. Hausmann. 2007. Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. J. Gen. Virol. 88:3249-3259.
30. Meyer, H., G. Sutter, and A. Mayr. 1991. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72:1031-1038.
31. Midgley, C. M., M. M. Putz, J. N. Weber, and G. L. Smith. 2008. Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax. J. Gen. Virol. 89:2992-2997.
32. Najera, J. L., C. E. Gomez, E. Domingo-Gil, M. M. Gherardi, and M. Esteban. 2006. Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J. Virol. 80:6033-6047.
33. Ng, A., D. C. Tscharke, P. C. Reading, and G. L. Smith. 2001. The vaccinia virus A41L protein is a soluble 30 kDa glycoprotein that affects virus virulence. J. Gen. Virol. 82:2095-2105.
34. O'Connor, M., M. Peifer, and W. Bender. 1989. Construction of large DNA segments in Escherichia coli. Science 244:1307-1312. (Pubitemid 19170500)
35. Okeke, M. I., O. Nilssen, and T. Traavik. 2006. Modified vaccinia virus Ankara multiplies in rat IEC-6 cells and limited production of mature virions occurs in other mammalian cell lines. J. Gen. Virol. 87:21-27.
36. Perkus, M. E., S. J. Goebel, S. W. Davis, G. P. Johnson, K. Limbach, E. K. Norton, and E. Paoletti. 1990. Vaccinia virus host range genes. Virology 179:276-286.
37. Perkus, M. E., S. J. Goebel, S. W. Davis, G. P. Johnson, E. K. Norton, and E. Paoletti. 1991. Deletion of 55 open reading frames from the termini of vaccinia virus. Virology 180:406-410.
38. Pires de Miranda, M., P. C. Reading, D. C. Tscharke, B. J. Murphy, and G. L. Smith. 2003. The vaccinia virus kelch-like protein C2L affects calcium-independent adhesion to the extracellular matrix and inflammation in a murine intradermal model. J. Gen. Virol. 84:2459-2471.
39. Reyrat, J. M., V. Pelicic, B. Gicquel, and R. Rappuoli. 1998. Counterselectable markers: untapped tools for bacterial genetics and pathogenesis. Infect. Immun. 66:4011-4017.
40. Rosel, J. L., P. L. Earl, J. P. Weir, and B. Moss. 1986. Conserved TAAATG sequence at the transcriptional and translational initiation sites of vaccinia virus late genes deduced by structural and functional analysis of the HindIII H genome fragment. J. Virol. 60:436-449.
41. Samuelsson, C., J. Hausmann, H. Lauterbach, M. Schmidt, S. Akira, H. Wagner, P. Chaplin, M. Suter, M. O'Keeffe, and H. Hochrein. 2008. Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J. Clin. Invest. 118:1776-1784.
42. Sancho, M. C., S. Schleich, G. Griffiths, and J. Krijnse-Locker. 2002. The block in assembly of modified vaccinia virus Ankara in HeLa cells reveals new insights into vaccinia virus morphogenesis. J. Virol. 76:8318-8334.
43. Sauer, B. 1987. Functional expression of the cre-lox site-specific recombination system in the yeast Saccharomyces cerevisiae. Mol. Cell. Biol. 7:2087-2096.
44. Staib, C., I. Drexler, and G. Sutter. 2004. Construction and isolation of recombinant MVA. Methods Mol. Biol. 269:77-100.
45. Stickl, H., V. Hochstein-Mintzel, A. Mayr, H. C. Huber, H. Schäfer, and A. Holzner. 1974. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA). Dtsch. Med. Wochenschr. 99:2386-2392.
46. Stittelaar, K. J., T. Kuiken, R. L. de Swart, A. G. van, H. W. Vos, H. G. Niesters, S. P. van, K. T. van der, L. S. Wyatt, B. Moss, and A. D. Osterhaus. 2001. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19:3700-3709.
47. Suter, M., C. Meisinger-Henschel, M. Tzatzaris, V. Hulsemann, S. Lukassen, N. H. Wulff, J. Hausmann, P. Howley, and P. Chaplin. 2009. Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain. Vaccine 27:7442-7450.
48. Sutter, G., and B. Moss. 1992. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. U. S. A. 89:10847-10851.
49. Sutter, G., A. Ramsey-Ewing, R. Rosales, and B. Moss. 1994. Stable expression of the vaccinia virus K1L gene in rabbit cells complements the host range defect of a vaccinia virus mutant. J. Virol. 68:4109-4116. (Pubitemid 24183004)
50. Sutter, G., and C. Staib. 2003. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr. Drug Targets Infect. Disord. 3:263-271.
51. Symons, J. A., E. Adams, D. C. Tscharke, P. C. Reading, H. Waldmann, and G. L. Smith. 2002. The vaccinia virus C12L protein inhibits mouse IL-18 and promotes virus virulence in the murine intranasal model. J. Gen. Virol. 83:2833-2844.
52. Symons, J. A., A. Alcami, and G. L. Smith. 1995. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81:551-560.
53. Symons, J. A., D. C. Tscharke, N. Price, and G. L. Smith. 2002. A study of the vaccinia virus interferon-gamma receptor and its contribution to virus virulence. J. Gen. Virol. 83:1953-1964.
54. Tartaglia, J., M. E. Perkus, J. Taylor, E. K. Norton, J. C. Audonnet, W. I. Cox, S. W. Davis, H. J. van der, B. Meignier, M. Riviere, B. Languet, and E. Paoletti. 1992. NYVAC: a highly attenuated strain of vaccinia virus. Virology 188:217-232.
55. Valderrama, F., J. V. Cordeiro, S. Schleich, F. Frischknecht, and M. Way. 2006. Vaccinia virus-induced cell motility requires F11L-mediated inhibition of RhoA signaling. Science 311:377-381. (Pubitemid 43132662)
56. Vollmar, J., N. Arndtz, K. M. Eckl, T. Thomsen, B. Petzold, L. Mateo, B. Schlereth, A. Handley, L. King, V. Hülsemann, M. Tzatzaris, K. Merkl, N. Wulff, and P. Chaplin. 2006. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 24:2065-2070.
57. von Krempelhuber, A., J. Vollmar, R. Pokorny, P. Rapp, N. Wulff, B. Petzold, A. Handley, L. Mateo, H. Siersbol, H. Kollaritsch, and P. Chaplin. 2010. A randomized, double-blind, dose-finding phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine 28:1209-1216.
58. Wang, S., Y. Zhao, M. Leiby, and J. Zhu. 2009. A new positive/negative selection scheme for precise BAC recombineering. Mol. Biotechnol. 42:110-116.
59. Wyatt, L. S., M. W. Carroll, C. P. Czerny, M. Merchlinsky, J. R. Sisler, and B. Moss. 1998. Marker rescue of the host range restriction defects of modified vaccinia virus Ankara. Virology 251:334-342.
60. Yao, X. D., and D. H. Evans. 2003. High-frequency genetic recombination and reactivation of orthopoxviruses from DNA fragments transfected into leporipoxvirus-infected cells. J. Virol. 77:7281-7290.
61. Yu, W., Q. Fang, W. Zhu, H. Wang, P. Tien, L. Zhang, and Z. Chen. 2010. One time intranasal vaccination with a modified vaccinia Tiantan strain MVTT(ZCI) protects animals against pathogenic viral challenge. Vaccine 28:2088-2096.
62. Zhang, Y., J. P. Muyrers, J. Rientjes, and A. F. Stewart. 2003. Phage annealing proteins promote oligonucleotide-directed mutagenesis in Escherichia coli and mouse ES cells. BMC. Mol. Biol. 4:1.